Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro

Cancer Immunology Immunotherapy

Volumn 42, Issue 3, 1996, Pages 193-199

  Pawelec, Graham ^a,b   Rehbein, Arnika ^a   Schlotz, Elke ^a   Da Silva, Paul ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

cellular immune response; myelogenous leukemia

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 4;

ARTICLE; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0029882074     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050270     Document Type: Article

References (22)

1. Barrett J, Guimaraes A, Cullis J, Goldman JM (1993) Immunological Characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia. Stem Cells 11: 104
2. Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S (1993) Human IL-10 is produced by both type-1 helper (Th1) and type-2 helper (Th2) T-cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 150: 353
3. Falkenburg JHF, Goselink HM, Van der Harst D, et al (1991) Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic lymphocytes-T. J Exp Med 174: 27
4. Hodge JW, Abrams S, Schlom J, Kantor JA (1994) Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 54: 5552
5. + T-cell clones and resting T-cells - specific inhibition of IL-2 production and proliferation. J Immunol 150: 4754
6. Matsuda M, Salazar F, Petersson M, et al (1994) Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 180: 2371
7. Mosmann TR, Coffman RL (1989) Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 46: 111
8. Pawelec G (1994) Immune surveillance of leukemia: rationale tor immunotherapy? Hematol Rev 8: 123
9. Pawelec G (1994) MHC-unrestricted immune surveillance of leukemia. Cancer Biotherapy 9: 265
10. Pawelec G, Busch FW (1988) Pretreatment of chronic myelogenous leukaemic blood samples with cytosine arabinoside prior to mixed lymphocyte culture typing. Transplantation 46: 607
11. Pawelec G, Schmidt H, Schneider E, Bühring HJ, Ehninger G (1988) Cellular immunological defects of chronic myelogenous leukaemia: partial dependence on busulphan therapy. Cancer Immunol Immunother 27: 89
12. Pawelec G, Schmidt H, Rehbein A, Busch F (1989) Anti-tumour activity in vitro in chronic myelogenous leukaemia revealed after treating peripheral cells with cytosine arabinoside. Cancer Immunol Immunother 29: 242
13. Pawelec G, Da Silva P, Max H, et al (1995) Relative roles of natural killer-mediated and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha. Leuk Lymphoma 18: 471
14. Sarawar SR, Sangster M, Coffman RL, Doherty PC (1994) Administration of anti-IFN-gamma antibody to beta(2)-microglobulin-deficient mice delays influenza virus clearance but does not switch the response to a T helper cell 2 phenotype. J Immunol 153: 1246
15. Schuudt K, Pawelec G (1991) Computerised transfer and processing of data from experiments measuring cellular proliferation by incorporation of tritiated thymidine. J Immunol Methods 138: 155
16. Somasundaram R, Advani SH, Gangal SG (1988) Propagation of cytotoxic effectors from chronic myeloid leukemia patients and cloning of cytotoxic T cells. Cancer Immunol Immunother 27: 183
17. Somasundaram R, Rao SGA, Advani SH, Gangal SG (1988) In vitro generation of effector cells cytotoxic to autologous targets from chronic myeloid leukemia patients in remission. Cancer Immunol Immunother 27: 177
18. Taga K, Mostowski H, Tosato G (1993) Human interleukin-10 can directly inhibit T-cell growth. Blood 81: 2964
19. Talpaz M (1994) Use of interferon in the treatment of chronic myelogenous leukemia. Semin Oncol 21: 3
20. Valiron O, Clemancey-Marcille G, Troesch A, et al (1988) Immunophenotype of blast cells in chronic myeloid leukemia. Leuk Res 12: 861
21. Van der Harst D, Goulmy E, Falkenburg JHF, et al (1994) Recognition of minor histocompatibility antigens on lymphocytic and myeloid leukemic cells by cytotoxic T-cell clones. Blood 83: 1060
22. Verfaillie CM, Miller WJ, Boylan K, McGlave PB (1992) Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 79: 1003